Tag:
FTC
Latest Headlines
Latest Headlines
Groups urge FTC to investigate vaccine 'bundling'
Several watchdog groups are calling upon the Federal Trade Commission to investigate Sanofi Pasteur and Merck for allegedly forcing doctors to buy bundled vaccines.
Less cash, more promises in pay-to-delay deals
The debate over pay-to-delay deals played out in microcosm at an American Bar Association panel yesterday. As Legal Times reports, the Federal Trade Commission's deputy assistant director Bradley
FTC: Pay-for-delay ban would save $2.67B
It's no coincidence that the Federal Trade Commission released new "pay for delay" numbers yesterday, just as the Congressional budget-cutting committee nears its deadline. The FTC wanted to
Sen. Schumer asks FTC to probe gray market mark-ups in drug shortages
U.S. Sen. Chuck Schumer (D-NY) has asked the Federal Trade Commission to investigate the gray marketers that appear to tack on hundreds- and even thousands-percent increases to hospitals for drugs in
FTC report IDs new twist on pay-to-delay
The Federal Trade Commission has found a new target in its quest to foster competition in the drug market: authorized generics. Some drugmakers are using promises to stay out of the authorized
FTC goes back to Teva on Cephalon deal
The Federal Trade Commission has requested additional information on Israel-based Teva Pharmaceutical Industries' planned acquisition of U.S. drugmaker Cephalon, potentially delaying regulatory
FTC mulls agency action against pay-for-delay
The Federal Trade Commission is considering using its rule-making power to stop so-called pay-for-delay deals between branded drugmakers and generics companies after failing to get judges or Congress
U.K. accuses Servier of generic-blocking, sues for £220M
The pay-for-delay battle is now in U.K. court. Health Secretary Andrew Lansley has sued the French drugmaker Servier for £220 million ($361.3 million), claiming that the company blocked generic
FTC asked to consider drug supply in pharma rulings
A U.S. lawmaker is appealing to the Federal Trade Commission to consider the implications on drug supply and pricing in pharma M&A activity. Senator Herb Kohl has written FTC Chairman Jon
FTC chief laments 63% boost in generic settlements
You can't accuse Federal Trade Commission Chairman Jon Leibowitz of being a quitter. The agency chief is on his generic settlements soapbox again, saying that the number of deals delaying copycat
